Analysis of BRCA1 promoter methylation may contribute to strategies for the identification of women who may benefit from PARP inhibition or other targeted therapies, as has occurred in BRCA associated ovarian cancer [54]. This evidence concerns the gene PARP1 and ovarian carcinoma.